Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M299Revenue $M0.2Net Margin (%)0Z-Score-3.9
Enterprise Value $M195EPS $-1.3Operating Margin %0F-Score3
P/E(ttm))0Cash Flow Per Share $0Pre-tax Margin (%)0Higher ROA y-yN
Price/Book3.410-y EBITDA Growth Rate %0Quick Ratio3.7Cash flow > EarningsY
Price/Sales05-y EBITDA Growth Rate %0Current Ratio3.7Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-95.0Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)1ROE % (ttm)-173.3Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M109ROI % (ttm)0Gross Margin Increase y-yN

Gurus Latest Trades with SNTA

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
SNTAJohn Burbank 2014-06-30 Sold Out -0.01%$3.97 - $4.48
($4.18)
$ 2.74-34%Sold Out0
SNTAJohn Burbank 2014-03-31 Buy 0.01%$4.28 - $7.01
($5.63)
$ 2.74-51%New holding, 46620 sh.46,620
SNTAJean-Marie Eveillard 2012-06-30 Sold Out -0.0035%$3.68 - $7.82
($4.69)
$ 2.74-42%Sold Out0
SNTAJean-Marie Eveillard 2012-03-31 Buy $4.22 - $5.66
($4.49)
$ 2.74-39%New holding, 200000 sh.200,000
SNTAMichael Price 2011-06-30 Sold Out -0.1%$4.45 - $6.23
($5.37)
$ 2.74-49%Sold Out0
SNTAMichael Price 2010-06-30 Buy 0.07%$2.67 - $4.79
($3.62)
$ 2.74-24%New holding, 118058 sh.118,058
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

SNTA is held by these Gurus:

Premium Most recent portfolio changes are included for Premium Members only!


SNTA: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Kovner BruceDirector, 10% Owner 2014-09-30Buy300,000$3.08-9.09view
Kovner BruceDirector, 10% Owner 2014-04-11Buy1,250,000$4.01-30.17view
Bahcall Safi RPresident and CEO 2013-11-13Buy20,000$3.75-25.33view
REARDON WILLIAM SDirector 2013-11-13Buy13,333$3.75-25.33view
Gollust Keith RDirector 2013-11-13Buy150,000$3.75-25.33view
Kovner BruceDirector, 10% Owner 2013-11-13Buy5,000,000$3.75-25.33view
Bahcall Safi RPresident and CEO 2013-06-28Buy10,000$5.03-44.33view
Kovner BruceDirector, 10% Owner 2013-06-27Buy150,000$4.71-40.55view
Kovner BruceDirector, 10% Owner 2013-06-26Buy500,000$4.53-38.19view
Kovner BruceDirector, 10% Owner 2013-06-21Buy250,000$4.39-36.22view

Press Releases about SNTA :

    Quarterly/Annual Reports about SNTA:

    News about SNTA:

    Articles On GuruFocus.com
    Top 4 Insider Buys of Last Week Jun 10 2013 
    Weekly CEO Buys Highlight: SNTA, MEI, PZG, MCHX, CMXI Jul 07 2012 
    Weekly CEO Buys Highlight: SNTA, MEI, PZG, MCHX, CMXI Jul 07 2012 
    These 4 Biotech Stocks Are a Buy Now Feb 08 2012 
    Synta Pharmaceuticals Inc. (SNTA) CEO Safi R Bahcall buys 5,000 Shares Mar 15 2011 
    Synta Pharmaceuticals Inc. (SNTA) VP, Fin. and Admin., CFO Keith S Ehrlich sells 2,537 Shares Mar 03 2011 
    MAGIC FORMULA INVESTING 2010 YEAR IN REVIEW -- Winners: MGIC, QCOR, SNTA, CF; Losers: SPMD, JTX Jan 01 2011 
    Synta Pharmaceuticals Inc. (SNTA) CEO Safi R Bahcall buys 10,000 Shares Jun 10 2010 
    Synta Pharmaceuticals Inc. (SNTA) CEO Safi R Bahcall buys 22,222 Shares Jan 12 2010 
    Synta Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 04 2009 

    More From Other Websites
    Synta Announces Presentation of Results from an Investigator-Sponsored Phase 1 Trial of Ganetespib... Dec 16 2014
    Synta Announces Presentation of Results from an Investigator-Sponsored Phase 1 Trial of Ganetespib... Dec 12 2014
    Synta Reports Inducement Grants to New Chief Operating Officer and New Chief Financial Officer Dec 10 2014
    Synta Reports Inducement Grants to New Chief Operating Officer and New Chief Financial Officer Dec 10 2014
    SYNTA PHARMACEUTICALS CORP Files SEC form 8-K, Change in Directors or Principal Officers, Financial... Dec 04 2014
    Synta Strengthens Management Team with Two Executive Appointments Dec 04 2014
    Synta Strengthens Management Team with Two Executive Appointments Dec 04 2014
    Synta Announces Presentation on Hsp90 inhibitor Drug Conjugate Platform at 26th EORTC-NCI-AACR... Nov 19 2014
    SYNTA PHARMACEUTICALS CORP Financials Nov 15 2014
    Synta to Present at the Stifel 2014 Healthcare Conference Nov 12 2014
    Synta to Present at the Stifel 2014 Healthcare Conference Nov 12 2014
    10-Q for Synta Pharmaceuticals Corp. Nov 09 2014
    Synta Pharmaceuticals Corp Earnings Call scheduled for 10:00 am ET today Nov 06 2014
    Synta beats 3Q profit forecasts Nov 06 2014
    Synta beats 3Q profit forecasts Nov 06 2014
    Synta Reports Third Quarter Financial Results and Provides Corporate Update Nov 06 2014
    Q3 2014 Synta Pharmaceuticals Corp Earnings Release - Before Market Open Nov 06 2014
    Synta Reports Third Quarter Financial Results and Provides Corporate Update Nov 06 2014
    SYNTA PHARMACEUTICALS CORP Files SEC form 10-Q, Quarterly Report Nov 06 2014
    Will Synta Pharmaceuticals (SNTA) Post a Wider Q3 Loss? Nov 05 2014

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK